US-based biotech company eFFECTOR Therapeutics has secured $38.6m in a series C venture financing round led by Pfizer Venture Investments (PVI).

The company plans to use the funds to progress the development of its MNK1/2 inhibitor, eFT508, into Phase II development.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

VenatoRx Pharmaceuticals has secured $42m in a series B venture financing round led by Versant Venture Management.

"VenatoRx Pharmaceuticals has secured $42m in a series B venture financing round led by Versant Venture Management."

The US-based biopharmaceutical company plans to use the funds for the development of its product portfolio.

Kezar Life Sciences, a biopharmaceutical company based in the US, has secured $50m in a series B venture financing round led by Cormorant Asset Management.

The company will direct the funds towards the development of its immunoproteasome inhibitor KZR-616.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact